Scionti says HIFU
offers an opportunity - in properly selected patients - to treat cancer with a much reduced side-effect profile that preserves quality of life, including less chance of urinary leakage and sexual issues, which are common results after a radical prostatectomy, the traditional treatment.
It combines the three essential components to efficiently perform a focal treatment: (i) state-of-the-art imaging to localize tumors with the use of magnetic resonance imaging (MRI) combined with real-time ultrasound, (ii) utmost precision of HIFU
treatment focused on identified targeted cancer areas only and (iii) immediate feedback on treatment efficacy utilizing Contrast-Enhanced Ultrasound Imaging.
transrectal system has already proven an effective way to transition from treating the entire prostate to treating only the known prostate cancer and the addition of the Sonatherm laparoscopic system allows us to offer an important new minimally invasive option for certain tumors," added Dr.
Moreover, little is known about salvage therapy for the 13% to 15% of patients with persistent local disease after HIFU
procedure awaiting approval in US [online article].
Marc Oczachowski concluded: "While we expand our expertise in HIFU
to further applications, we remain fully focused on developing our HIFU
technology and adapt it to the current focal therapy trend to treat prostate cancers.
Although the HIFU
treatment has been used only on benign thyroid nodules so far, HIFU
is used to treat prostate cancer, and it can probably be used to treat thyroid cancer in the future, Dr.
appears to sidestep some typical side effects of surgery and radiation, it's not yet clear whether the novel approach is as successful at curing cancers as those standard treatments are.
is the entity through which USHIFU conducts its international business operations and makes the HIFU
technologies available to patients at centers outside the United States where such use is authorized, approved or otherwise permitted.
Peretsman, a board-certified urologist that has performed over 2,800 surgical prostatectomies, has treated several hundred prostate cancer patients with Sonablate HIFU
over the past 10 years.
Until a validated definition of biochemical failure is defined, HIFU
treated patients must be followed with post-treatment transrectal ultrasound-guided prostate biopsy.
Our intent has always been to continue building the HIFU
device product pipeline, and acquiring the Sonatherm is a significant milestone in that process," said US HIFU
's chief executive officer Steve Puckett, Jr.
Then, an HIFU
operator would focus the sound waves on the ruptured blood vessel and increase their intensity to 1 million times that used for imaging.
is a minimally invasive novel medical technology through which intersecting, precision focused ultrasound waves raise the temperature of the target tissue to 80-90 degrees Celsius in two to three seconds, effectively destroying the targeted cancerous tissues.
3, 2015 /PRNewswire/ -- The FDA has fully approved the non-surgical, non-invasive treatment for prostate cancer known as HIFU
or High Intensity Focused Ultrasound Therapy.